Introduction
Ehlers-Danlos Syndrome (EDS) is the term used for a group of relatively rare genetic disorders of the connective tissue that are characterized by one or several features including hyperextensibility of the skin, joint hypermobility, and tissue fragility. The general frequency of the EDSs is 1 in 5000. 1 Over the past two decades, the Villefranche Nosology, which delineated six subtypes, has been widely used as the standard for clinical diagnosis of EDS. However, the 2017 international classification of EDS recognizes 13 subtypes. 2 The genetic basis for most types of EDS has been defined, except for the hypermobility type (which is likely to be genetically heterogeneous), and genetic tests may be useful for the diagnosis of several of these alterations. Clinical diagnoses are based on a series of major and minor criteria, which differ according to the type of EDS. Additionally, patients may have superimposed characteristics from different types, and are not easily classified. 3 The Cardiac-Valvular EDS (cvEDS) is a subtype of EDS with inheritance autosomal recessive with severe progressive cardiac-valvular problems (aortic valve, mitral valve), skin hyperextensibility, atrophic scars, thin skin, easy bruising and joint hypermobility (generalized or restricted to small joints) as the major criteria. While inguinal hernia, pectus deformity (especially excavatum), joint dislocations, foot deformities: pes planus, pes planovalgus, hallux valgus form part of the minor criteria. Molecular screening by Sanger sequencing of COL1A2 or targeted resequencing of a gene panel that includes COL1A2 is indicated for diagnosis verification. 2 
Timeline Case presentation
A 46-year-old patient with a past medical history of hypertension, HIV positive on treatment with antiretrovirals was referred for an echocardiographic study of a heart murmur. Physical examination revealed moderate jugular venous distention and large C-V waves. No right or left ventricular heave was found, and cardiac auscultation confirmed a Grade 4/6 diastolic decrescendo murmur best heard in the left second intercostal space; Grade 3/6 holosystolic murmur best heard at the left lower sternal border that accentuates with inspiration; no S3 or S4. He was in NYHA Class I and denied any other cardiac symptoms. Electrocardiogram shown sinus rhythm, right bundle branch block with qRs of 160 ms, left anterior fascicular, and a first-degree auriculoventricular (AV) block ( Figure 1 Presence of severe PR with marked right ventricular dilatation, even in an asymptomatic patient, in most cases will require valvular intervention in order to avoid the development of heart failure. However, in patients with EDS, where the healing conditions are seriously affected, the valve replacement is much more controversial. In this patient, the heart team initially decided medical treatment and evolutionary control. Six months later he remains without any symptoms, imaging testing does not evidence changes in right ventricular dimensions and parameters of the systolic function.
Discussion
The cvEDS is an infrequent subtype of EDS with classical mitral or aortic valve involvement. In this occasion, we presented the case report of prolapse and regurgitation of all the heart valves. Monitoring and cardiological treatment will depend on the degree of valvular disease. Severe PR is the most significative finding of our patient and could determine progressive right ventricular dilatation will subsequently lead to right ventricular failure and the appearance of symptoms over the time. 4 The timing of intervention is a crucial factor for long-term patient morbidity and survival. Surgical pulmonary valve replacement is a well-established treatment strategy with <1% periprocedural mortality when performed by an experienced surgeon, and excellent long-term outcome with >60% freedom from reoperation at 10 years. 5 On the other hand, there are very little evidence of cardiac interventions in patients with EDS. Wiesmann et al. 6 described the recommendations on pre-and perioperative management of this patient based on the analysis of small cohorts, isolated clinical cases, and recommendation of experts. Making clear that any type of intervention presumes an important morbidity and mortality. Orotracheal intubation may cause dislocation of the temporomandibular joint. The fragility of the internal organs can promote spontaneous ruptures. Attempts should be made to avoid arterial punctures in order to prevent rupture of the vessel wall. The presence of nausea and vomiting can promote oesophageal rupture for which a correct antiemetic prophylaxis will have to be carried out. These are individuals with a high risk of bleeding and even a normal laboratory does not exclude the risk of serious bleeding, thus the administration of blood products should be taken into account. Choosing the prosthetic valve to prefer is another relevant point. Permanent anticoagulation of mechanical valves is not desired since it would add an additional risk of bleeding. Bioprosthetic valves could require temporary oral anticoagulation for 3-6 months after pulmonary valve replacement due to bioprosthetic valve thrombosis. 7 Percutaneous replacement is an option for patients with prosthetic pulmonary valve regurgitation. However, native PR is rarely candidate for percutaneous replacement. The configuration of the native right ventricular outflow tract is highly variable and depends on the type of initial intervention; thus, there is an increased risk of perivalvular regurgitation and device embolization. Although percutaneous pulmonary valve implantation has been performed in some cases of native PR, limited data are available to support this approach. 8 The freedom from reintervention after percutaneous pulmonary valve replacement is >90% at 1 year, but long-term data are lacking. 9 Patients with moderate or greater PR should also undergo evaluation by cardiovascular magnetic resonance (CMR) if available, which enables quantitative assessment of PR and of right ventricular size and function, which may impact the timing of intervention. Cardiovascular magnetic resonance imaging is the preferred modality for the assessment of right ventricular enlargement and dysfunction, important sequelae of long-standing severe PR. 10 Surgical pulmonary valve replacement is recommended for symptomatic, severe PR. 11 In addition, pulmonary valve replacement for asymptomatic severe PR in the setting of severe right ventricular dilation and/or dysfunction (CMR-derived right ventricular end-diastolic volume >150 mL/m 2 , end-systolic volume >80 mL/m 2 , ejection fraction <47%, 7 or symptomatic atrial and/or ventricular arrhythmias) is also recommended.
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Cardiopulmonary exercise testing provides prognostic information and may also be useful in deciding the timing of pulmonary valve replacement in patients with exertional symptoms out of proportion to disease severity and the degree of right ventricular dysfunction. 13 It is helpful in screening for exercise-induced arrhythmias as well as in the risk stratification for sudden death.
Conclusion
The EDS is part of a group of connective tissue diseases that affect the synthesis and processing of collagen leading to alterations in the structure of many tissues and organs. The progressive and severe involvement of the heart valves forms part of the cvEDS. The compromise of the four cardiac valves is a rare and exceptional fact. In the present case, the treatment of the severe PR is very challenging. The occurrence of symptoms or the presence of right ventricular dysfunction with increased volumes evaluated by CMR in asymptomatic patients determine indications of valvular replacement to avoid Figure 6 Continuous Doppler analysis of pulmonary regurgitation, a jet was registered that occupies all the diastole, with a pressure halftime of 161 ms (A). Transthoracic echocardiography of the pulmonary valve, thickened valves, and prolapse of its leaflets was observed (B). Pulmonary regurgitation jet was estimated into moderate to severe degree (C). PA, pulmonary artery; RVOT, right ventricle outflow tract.
